Akili, Inc.(formerly Social Capital Suvretta Holdings Corp. I) , a commercialized company that develops digital therapies that combine science and technology to address cognitive disorders such as patient inattention, memory loss, difficulty learning new skills, and difficulty making decisions, is a new category of software-based medicine. The company has used its approach to technology that targets the brain directly to build a new class of drugs - drugs that have been validated in clinical trials, such as drugs or medical devices. The company's platform is powered by a proprietary therapeutic engine designed to target cognitive disorders in the brain, informed by decades of research and validated by a rigorous clinical program.
No Data